Literature DB >> 1673048

Benzodiazepine anti-anxiety agents: prevalence and correlates of use in a southern community.

M Swartz1, R Landerman, L K George, M L Melville, D Blazer, K Smith.   

Abstract

BACKGROUND: Benzodiazepine anti-anxiety agents are the most widely prescribed psychotherapeutic drugs in the United States today. Recent evidence, however, suggests that their use may be decreasing.
METHODS: We examine the population prevalence and correlates of use of benzodiazepine anxiolytics at the Duke site of the NIMH-sponsored Epidemiologic Catchment Area project.
RESULTS: Bivariate analysis of use patterns for the drugs revealed demographic predictors similar to those reported in previous studies: increased likelihood of use by the elderly, Whites, women, the less educated, and the separated or divorced. Use is also associated with symptoms of psychic distress, negative life events, use of health care services, and diagnoses of affective disorder, agoraphobia with panic, and panic disorder. Age, sex, race, education, and marital status remain associated with non-hypnotic benzodiazepine use in a logistic regression analysis.
CONCLUSIONS: Multivariate analyses of these data indicate that when potential confounding factors are controlled, age, sex, race, education, and marital status are significantly related to benzodiazepine anxiolytic use but the effects of sex and education are mediated by intervening variables. Implications of these findings are discussed particularly in relation to high levels of use in the elderly.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673048      PMCID: PMC1405082          DOI: 10.2105/ajph.81.5.592

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  19 in total

1.  Benzodiazepines of long and short elimination half-life and the risk of hip fracture.

Authors:  W A Ray; M R Griffin; W Downey
Journal:  JAMA       Date:  1989-12-15       Impact factor: 56.272

2.  Patterns of benzodiazepine use in Great Britain as measured by a general population survey.

Authors:  G C Dunbar; M H Perera; F A Jenner
Journal:  Br J Psychiatry       Date:  1989-12       Impact factor: 9.319

3.  Age differences in life events: a multivariate controlled analysis.

Authors:  D C Hughes; D G Blazer; L K George
Journal:  Int J Aging Hum Dev       Date:  1988

4.  Benzodiazepine overuse-misuse.

Authors:  R I Shader; D J Greenblatt
Journal:  J Clin Psychopharmacol       Date:  1984-06       Impact factor: 3.153

5.  Prescribing of psychotropic medication by primary care physicians and psychiatrists.

Authors:  R S Beardsley; G J Gardocki; D B Larson; J Hidalgo
Journal:  Arch Gen Psychiatry       Date:  1988-12

6.  National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity.

Authors:  L N Robins; J E Helzer; J Croughan; K S Ratcliff
Journal:  Arch Gen Psychiatry       Date:  1981-04

7.  Drug use and expenditures in 1982.

Authors:  C Baum; D L Kennedy; M B Forbes; J K Jones
Journal:  JAMA       Date:  1985-01-18       Impact factor: 56.272

8.  The Social Readjustment Rating Scale.

Authors:  T H Holmes; R H Rahe
Journal:  J Psychosom Res       Date:  1967-08       Impact factor: 3.006

9.  The NIMH Epidemiologic Catchment Area program. Historical context, major objectives, and study population characteristics.

Authors:  D A Regier; J K Myers; M Kramer; L N Robins; D G Blazer; R L Hough; W W Eaton; B Z Locke
Journal:  Arch Gen Psychiatry       Date:  1984-10

10.  Prevalence and correlates of the long-term regular use of anxiolytics.

Authors:  G D Mellinger; M B Balter; E H Uhlenhuth
Journal:  JAMA       Date:  1984-01-20       Impact factor: 56.272

View more
  14 in total

1.  Patterns of psychotropic medicine use and related diseases across educational groups: national cross-sectional survey.

Authors:  Merete W Nielsen; Ebba Holme Hansen; Niels Kristian Rasmussen
Journal:  Eur J Clin Pharmacol       Date:  2004-03-16       Impact factor: 2.953

2.  How a novel programme for increasing awareness of health professionals resulted in a 14% decrease in patients using excessive doses of psychotropic drugs in western France.

Authors:  C Victorri-Vigneau; G Basset; P Jolliet
Journal:  Eur J Clin Pharmacol       Date:  2006-02-28       Impact factor: 2.953

3.  Some current factors influencing the prescribing and use of psychiatric drugs.

Authors:  R L Poulsen
Journal:  Public Health Rep       Date:  1992 Jan-Feb       Impact factor: 2.792

4.  Variations in anxiolytic and hypnotic prescribing by GPs: a cross-sectional analysis using data from the UK Quality and Outcomes Framework.

Authors:  Zoi Tsimtsiou; Mark Ashworth; Roger Jones
Journal:  Br J Gen Pract       Date:  2009-06       Impact factor: 5.386

Review 5.  The effects of medication use in transcranial direct current stimulation: A brief review.

Authors:  Molly E McLaren; Nicole R Nissim; Adam J Woods
Journal:  Brain Stimul       Date:  2017-10-12       Impact factor: 8.955

6.  Initial 3-month usage characteristics predict long-term use of benzodiazepines: an 8-year follow-up.

Authors:  Rolf van Hulten; K Bart Teeuw; Albert Bakker; Hubert G Leufkens
Journal:  Eur J Clin Pharmacol       Date:  2003-02-07       Impact factor: 2.953

7.  Sedatives and hypnotics in Stockholm: social factors and kinds of use.

Authors:  G Blennow; A Romelsjö; H Leifman; A Leifman; G Karlsson
Journal:  Am J Public Health       Date:  1994-02       Impact factor: 9.308

Review 8.  Current benzodiazepine issues.

Authors:  J H Woods; G Winger
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

9.  Correlates and prevalence of benzodiazepine use in community-dwelling elderly.

Authors:  P P Gleason; R Schulz; N L Smith; J T Newsom; P D Kroboth; F J Kroboth; B M Psaty
Journal:  J Gen Intern Med       Date:  1998-04       Impact factor: 5.128

10.  Benzodiazepine use among adults residing in the urban settlements of Karachi, Pakistan: a cross sectional study.

Authors:  Saleem P Iqbal; Syed Ahmer; Salima Farooq; Yasmin Parpio; Ambreen Tharani; Rashid A M Khan; Mohammad Zaman
Journal:  Subst Abuse Treat Prev Policy       Date:  2011-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.